Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.
about
Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8⁺ T Cell EpitopesModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesDendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 MiceNovel viral vectored vaccines for the prevention of influenza.Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesDirect presentation is sufficient for an efficient anti-viral CD8+ T cell response.Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine modelPreclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-β-dependent induction of pro-apoptotic Noxa.Influenza A virus infection of human primary dendritic cells impairs their ability to cross-present antigen to CD8 T cells.Secreted immunodominant Mycobacterium tuberculosis antigens are processed by the cytosolic pathway.Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensInterplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells.A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.Reverse vaccinology: developing vaccines in the era of genomicsThe DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice.DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adultsModified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation.Viral MHC class I inhibition evades CD8+ T-cell effector responses in vivo but not CD8+ T-cell priming.Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimenCorrelation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation.Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradationThe cell biology of cross-presentation and the role of dendritic cell subsets.Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccinesSystemic toll-like receptor ligation and selective killing of dendritic cell subsets fail to dissect priming pathways for anti-vaccinia virus CD8⁺ T cellsDesigning CD8+ T cell vaccines: it's not rocket science (yet).Clinical applications of attenuated MVA poxvirus strain.Lymph node - an organ for T-cell activation and pathogen defense.CD8+ T Cells Orchestrate pDC-XCR1+ Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming.Rad50-CARD9 interactions link cytosolic DNA sensing to IL-1β production.Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo.Active dissemination of cellular antigens by DCs facilitates CD8(+) T-cell priming in lymph nodes.Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8(+) T Cell Responses Independently of Transgene Expression in DCs.
P2860
Q28647428-30ED343C-88CD-4DE5-95F2-89756C6628A1Q30209342-BC77EF8E-98A2-4C39-8ECC-49B7071BA034Q30318566-159C5DEC-C38B-4A80-A429-9897AB9C143EQ30375489-F8E578E0-628F-4F28-A196-3FA8526CBBFDQ30375979-A0BB7700-60B7-4758-94B8-1EC0318C27D7Q30392456-B105F228-A351-4E7B-9129-584DF5BC9C50Q30418570-7C8C069D-5063-4723-8860-111AAA5FE67BQ30973875-D3D3BA93-1F1D-4912-91C5-FC6B35B5D74DQ33440600-24DEE19B-E86D-4347-84F6-FC52A1A6C054Q33532640-FA2B8553-3B18-4F9C-A382-6E076EC9A31FQ33632203-A18CC099-E289-41FC-B696-BE4DE002A696Q33826983-A64C20AB-605F-42A6-9407-EF4116D5C97CQ33916776-B0C4B3EE-8AEB-40E3-8CAD-5C3F1E4CEEF0Q33941041-9DF45C73-6CB2-446F-B0C2-48C1A7C7EDDBQ34192846-39777074-204D-41E4-AC53-79C2F2E7D289Q34335032-CAD826BA-2853-4DE7-875D-4F1CC0444C01Q34465228-0F229379-E144-4A06-B7A2-8A370EE0A332Q34982651-7D1842F4-7A3B-4296-8389-C8B9C9996276Q35367108-B713880D-C453-4E98-ACE6-88AD1131F314Q35873940-FCC74645-C3B8-4130-AF64-6905E1A3156EQ35913709-151D3596-2520-43D2-B89F-9B696EABAA0CQ35940696-A88F3519-FC68-4F88-813D-0E3E342CCE8BQ35943471-7FBC5EE4-C1CE-4AA4-B9B7-BF2777B60C51Q36436950-9B4FD1BC-4CDA-4AF7-BF51-9DFC4F9C94FFQ36456190-13B5FCBF-744B-492B-8198-878C45216033Q36488676-82DC166B-E09C-4CB7-A209-1254554BAA9CQ36619698-C13B6FD9-93AA-4370-BC86-022AE3A94527Q36849770-B7610FE9-8CA2-4D43-9471-28EEDCF19AA7Q36983796-521C1385-1946-4106-B848-1DD02FEE124FQ37082455-FDE7260F-B978-46B8-98D7-E5343CD6AAF8Q37196054-A5610630-B07C-4281-B8F6-6FA201058530Q37254348-00664831-CC6F-4D01-8F6F-BD3BCC31BC07Q37744071-8BFB4315-1B26-4D5A-80D2-CD27310B7618Q38156198-D163FDB6-58FB-4AC1-849A-99634A96C498Q38810913-B5FB0031-7DCC-4D39-A5AB-AF677967DE11Q38964925-0A801C94-B393-49C3-BF91-3A2D887AC47FQ39000597-8A981B65-BBE2-4BDB-842A-BD0614FAA5CAQ39320211-F3B59EC1-2902-4323-A6E1-78A41BC97A5DQ40057658-928F177B-1B15-4CE2-8708-380AABD981EFQ40117829-618A707D-43B9-48A3-8E0D-9B5D79DACB1D
P2860
Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Cross-priming of cytotoxic T c ...... virus Ankara vector vaccines.
@ast
Cross-priming of cytotoxic T c ...... virus Ankara vector vaccines.
@en
type
label
Cross-priming of cytotoxic T c ...... virus Ankara vector vaccines.
@ast
Cross-priming of cytotoxic T c ...... virus Ankara vector vaccines.
@en
prefLabel
Cross-priming of cytotoxic T c ...... virus Ankara vector vaccines.
@ast
Cross-priming of cytotoxic T c ...... virus Ankara vector vaccines.
@en
P2093
P2860
P356
P1433
P1476
Cross-priming of cytotoxic T c ...... a virus Ankara vector vaccines
@en
P2093
Ingo Drexler
Ronny Ljapoci
Wolfgang Kastenmuller
P2860
P304
11925-11936
P356
10.1128/JVI.00903-07
P407
P577
2007-08-15T00:00:00Z